CTOs on the Move


 
Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.lupin.com
  • Harborplace Tower 111 South Calvert Street 21st Floor
    Baltimore, MD USA 21202
  • Phone: 410.576.2000

Executives

Name Title Contact Details
Marc Bowman
Associate Director of Information Technology Profile

Similar Companies

Pharmachem Labs

Pharmachem Laboratories, Inc., is a leading manufacturer and supplier of value-added nutritional ingredients and bulk raw materials. We offer an exclusive list of trademarks and catalogue of products, as well as custom-manufacturing, and research and

Newport Healthcare

Newport Healthcare is changing the face of behavioral health services for teens, young adults and their families by providing sustainable healing.

Net-Rx

Net-Rx is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Antigen Laboratories

Antigen Laboratories is a Liberty, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.